Cytotoxic aldehydes as possible markers for childhood cancer

被引:69
作者
Yazdanpanah, M
Luo, XP
Lau, RB
Greenberg, M
Fisher, LJ
Lehotay, DC
机构
[1] HOSP SICK CHILDREN, DEPT PEDIAT LAB MED, DIV CLIN BIOCHEM, TORONTO, ON M5G 1X8, CANADA
[2] HOSP SICK CHILDREN, DEPT PEDIAT, DIV HEMATOL ONCOL, TORONTO, ON M5G 1X8, CANADA
[3] UNIV TORONTO, TORONTO, ON, CANADA
关键词
aldehydes; oxidative stress; foe radicals; cancer; lipid peroxidation; doxorubicin; carnitine; mass spectrometry;
D O I
10.1016/S0891-5849(97)00070-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Concentrations of 22 known aldehydes (byproducts of lipid peroxidation), 5 acyloins, free and total carnitine and acylcarnitines were measured in plasma and urine obtained from pediatric patients with various forms of cancer before any treatment, and following treatment with doxorubicin or daunorubicin. Aldehydes, before the initiation of chemotherapy, were significantly elevated in cancer patients compared to controls. Aldehydes such as hexanal, heptanal, and malondialdehyde were strikingly higher in samples from cancer patients, while trans 4-cis-4-decenal was the prominent aldehyde in the blood of controls. In addition, in each form of cancer the pattern of aldehydes appeared to be unique when compared to controls, or to others forms of cancer, In cancer patients receiving chemotherapy there was a general trend toward a reduction 24 h after both the first and after the fifth doxorubicin dose. These changes however were not significant statistically due to large inter-patient variation. Free and total plasma carnitine levels remained in the normal range, and there a ere no abnormal acylcarnitines detected in urine, Possible hypotheses to explain the elevations in aldehydes, and the reasons for the changed aldehyde profiles in different forms of cancer are discussed. (C) 1997 Elsevier Science Inc.
引用
收藏
页码:870 / 878
页数:9
相关论文
共 34 条
[1]  
ALI MK, 1994, CANCER-AM CANCER SOC, V74, P182, DOI 10.1002/1097-0142(19940701)74:1<182::AID-CNCR2820740129>3.0.CO
[2]  
2-2
[3]   THE CAUSES AND PREVENTION OF CANCER [J].
AMES, BN ;
GOLD, LS ;
WILLETT, WC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (12) :5258-5265
[4]   ADRIAMYCIN-INDUCED HEPATIC AND MYOCARDIAL LIPID-PEROXIDATION AND DNA-DAMAGE, AND ENHANCED EXCRETION OF URINARY LIPID METABOLITES IN RATS [J].
BAGCHI, D ;
BAGCHI, M ;
HASSOUN, EA ;
KELLY, J ;
STOHS, SJ .
TOXICOLOGY, 1995, 95 (1-3) :1-9
[5]  
BARONZIO G, 1994, ANTICANCER RES, V14, P1145
[6]   ANTHRACYCLINE ANTIBIOTICS IN CANCER-THERAPY - FOCUS ON DRUG-RESISTANCE [J].
BOOSER, DJ ;
HORTOBAGYI, GN .
DRUGS, 1994, 47 (02) :223-258
[7]  
BOWEN PE, 1995, AM J CLIN NUTR, V62, P1403
[8]   DIRECT CHARACTERIZATION OF PROTEIN ADDUCTS OF THE LIPID-PEROXIDATION PRODUCT 4-HYDROXY-2-NONENAL USING ELECTROSPRAY MASS-SPECTROMETRY [J].
BRUENNER, BA ;
JONES, AD ;
GERMAN, JB .
CHEMICAL RESEARCH IN TOXICOLOGY, 1995, 8 (04) :552-559
[9]   MEMBRANE FATTY-ACID MODIFICATION IN TUMOR-CELLS - A POTENTIAL THERAPEUTIC ADJUNCT [J].
BURNS, CP ;
SPECTOR, AA .
LIPIDS, 1987, 22 (03) :178-184
[10]  
DELEONARDIS V, 1987, INT J CLIN PHARM RES, V7, P307